Validity of a two-antibody testing algorithm for mismatch repair deficiency testing in cancer; a systematic literature review and meta-analysis

por Aiyer, K. T. S., Doeleman, T., Ryan, N. A., Nielsen, M., Crosbie, E. J., Smit, V. T. H. B. M., Morreau, H., Goeman, J. J., Bosse, T.
Publicado 2022

Cardiovascular risk factors: The effects of ageing and smoking on the immune system, an observational clinical study

por Grievink, H. W., Smit, V., Huisman, B. W., Gal, P., Yavuz, Y., Klerks, C., Binder, C. J., Bot, I., Kuiper, J., Foks, A. C., Moerland, M.
Publicado 2022

Comment on: The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer

por Mesker, W E, Dekker, T J A, de Kruijf, E M, Engels, C C, van Pelt, G W, Smit, V T H B M, Tollenaar, R A E M
Publicado 2015

Prognostic value of tumor–stroma ratio combined with the immune status of tumors in invasive breast carcinoma

por Vangangelt, K. M. H., van Pelt, G. W., Engels, C. C., Putter, H., Liefers, G. J., Smit, V. T. H. B. M., Tollenaar, R. A. E. M., Kuppen, P. J. K., Mesker, W. E.
Publicado 2017

Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma

por Engels, C C, Fontein, D B Y, Kuppen, P J K, de Kruijf, E M, Smit, V T H B M, Nortier, J W R, Liefers, G J, van de Velde, C J H, Bastiaannet, E
Publicado 2014

Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients

por van Nes, J G H, Smit, V T H B M, Putter, H, Kuppen, P J, Kim, S J, Daito, M, Ding, J, Shibayama, M, Numada, S, Gohda, K, Matsushima, T, Ishihara, H, Noguchi, S, van de Velde, C J H
Publicado 2009

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy:...

por Engels, C. C., Charehbili, A., van de Velde, C. J. H., Bastiaannet, E., Sajet, A., Putter, H., van Vliet, E. A., van Vlierberghe, R. L. P., Smit, V. T. H. B. M., Bartlett, J. M. S., Seynaeve, C., Liefers, G. J., Kuppen, P. J. K.
Publicado 2015

Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters

por Versluis, M A, de Jong, R A, Plat, A, Bosse, T, Smit, V T, Mackay, H, Powell, M, Leary, A, Mileshkin, L, Kitchener, H C, Crosbie, E J, Edmondson, R J, Creutzberg, C L, Hollema, H, Daemen, T, de Bock, G H, Nijman, H W
Publicado 2015

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemoth...

por de Groot, A. F., Blok, E. J., Charehbili, A., Engels, C. C., Smit, V. T. H. B. M., Dekker-Ensink, N. G., Putter, H., Meershoek-Klein Kranenbarg, E., van de Velde, C. J. H., Liefers, G. J., Nortier, J. W. R., Kuppen, P. J. K., van der Burg, S. H., Kroep, J. R.
Publicado 2019

Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach

por Dekker, T. J. A., ter Borg, S., Hooijer, G. K. J., Meijer, S. L., Wesseling, J., Boers, J. E., Schuuring, E., Bart, J., van Gorp, J., Bult, P., Riemersma, S. A., van Deurzen, C. H. M., Sleddens, H. F. B. M., Mesker, W. E., Kroep, J. R., Smit, V. T. H. B. M., van de Vijver, M. J.
Publicado 2015

Erratum to: Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach

por Dekker, T. J. A., ter Borg, S., Hooijer, G. K. J., Meijer, S. L., Wesseling, J., Boers, J. E., Schuuring, E., Bart, J., van Gorp, J., Bult, P., Riemersma, S. A., van Deurzen, C. H. M., Sleddens, H. F. B. M., Mesker, W. E., Kroep, J. R., Smit, V. T. H. B. M., van de Vijver, M. J.
Publicado 2015

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer

por de Boer, S M, Wortman, B G, Bosse, T, Powell, M E, Singh, N, Hollema, H, Wilson, G, Chowdhury, M N, Mileshkin, L, Pyman, J, Katsaros, D, Carinelli, S, Fyles, A, McLachlin, C M, Haie-Meder, C, Duvillard, P, Nout, R A, Verhoeven-Adema, K W, Putter, H, Creutzberg, C L, Smit, V T H B M
Publicado 2018

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

por de Groot, S., Janssen, L. G. M., Charehbili, A., Dijkgraaf, E. M., Smit, V. T. H. B. M., Kessels, L. W., van Bochove, A., van Laarhoven, H. W. M., Meershoek-Klein Kranenbarg, E., van Leeuwen-Stok, A. E., van de Velde, C. J. H., Putter, H., Nortier, J. W. R., van der Hoeven, J. J. M., Pijl, H., Kroep, J. R.
Publicado 2015

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

por Wortman, B. G., Creutzberg, C. L., Putter, H., Jürgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen-Banasik, E. M., Mens, J. W. M., Slot, A., Kroese, M. C. Stenfert, van Triest, B., Nijman, H. W., Stelloo, E., Bosse, T., de Boer, S. M., van Putten, W. L. J., Smit, V. T. H. B. M, Nout, R. A.
Publicado 2018